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Abstract In recent years, molecular imaging gained sig-
niﬁcant importance in biomedical research. Optical imaging
developed into a modality which enables the visualization
and quantiﬁcation of all kinds of cellular processes and
cancerous cell growth in small animals. Novel gene reporter
mice and cell lines and the development of targeted and
cleavable ﬂuorescent ‘‘smart’’ probes form a powerful
imaging toolbox. The development of systems collecting
tomographic bioluminescence and ﬂuorescence data
enabled even more spatial accuracy and more quantitative
measurements. Here we describe various bioluminescent
and ﬂuorescent gene reporter models and probes that can be
used to speciﬁcally image and quantify neovascularization
or the angiogenic process itself.
Keywords Angiogenesis  Bioluminescence 
Fluorescence  Molecular imaging  Optical imaging
Introduction
Optical imaging
Optical imaging is a very versatile, sensitive and powerful
tool for molecular imaging in small animals. It is based on
the detection of photons in the visible light spectrum
emitted from living cells, tissues or animals and can be
divided in two main modalities, bioluminescence imaging
(BLI) and ﬂuorescence imaging (FLI). Optical imaging of
angiogenesis and existing vasculature is currently domi-
nated by FLI-based imaging models, but there are several
interesting BLI models as well. This review provides an
overview of the available optical imaging models that can
be used within angiogenesis related research.
Bioluminescence imaging
Bioluminescence imaging has been developed over the last
decade as a tool for molecular imaging of small laboratory
animals, enabling the study of ongoing biological processes
such as tumor growth and metastasis and gene expression
in vivo [1]. All bioluminescent reporter systems are based
on the detection of photons produced in an enzymatic
reaction in which a substrate, like luciferin or coelerent-
arazin, is oxidated by an enzyme, luciferase. There are
many different kinds of luciferases occurring in nature and
being adapted for research. The most commonly used
luciferase for molecular imaging purposes is the one
extracted from the North American ﬁreﬂy (Photinus py-
ralis; FLuc) emitting light with a broad emission spectrum
and a peak around 560 nm but other useful luciferases have
also been cloned from corals (Tenilla), jellyﬁsh (Aequo-
rea), several bacterial species (Vibrio ﬁscheri, V. harveyi)
and red or green click beetle (Pyrophorus plagiophthala-
mus) which have been optimized to produce green–orange
(544 nm) or red (611 nm) light after oxidizing luciferin.
Luciferases from the anthozoan sea pansy (Renilla
reniformis) and the marine copepod (Gaussia princeps)
react with coelenterazine and are ATP-independent to
produce blue light with peak emission at approximately
480 nm. Despite the blue emission wavelength of these
enzymes, limited biodistribution and rapid kinetics of
coelerentarazin in small animals, these luciferases have
been proven very useful for in vivo applications for
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DOI 10.1007/s10456-010-9168-ymolecular imaging [2–6]. Because the substrates luciferin
and coelentarazin for ﬁreﬂy luciferase (FFluc) and Gaussia
luciferase (Gluc), respectively, show no crossreactivity,
concomitantly imaging of distinct cell populations that
either express FFluc or Gluc can be performed within the
same animal.
BLI reporter systems are especially suitable for bio-
medical research purposes due to the extremely low
background signal, high signal to noise ratio, non-invasive
character, short acquisition time (seconds to minutes) and
the possibility to measure more animals at once (high
throughput).
Fluorescence imaging
In contrast to BLI, ﬂuorescence imaging is not based on the
production of photons by an enzymatic reaction; instead, a
ﬂuorescent compound (ﬂuorophore) can be exited by
photons of a certain wavelength from an external light
source. Upon relaxation to its ground state, the ﬂuorophore
emits photons at a different wavelength. These emitted
photons are the signal which is used for imaging. Similar to
BLI, whole body FLI enables tracking of tumor growth and
metastasis, gene expression, angiogenesis and bacterial
infection, quantitatively (reviewed in Hoffman [7]).
There is a wide range of ﬂuorophores available, ranging
from ﬂuorescent dyes and nanoparticles, like quantum dots,
to ﬂuorescent proteins which can be expressed in trans-
genic models. Each ﬂuorophore has several characteristics
amongst which the excitation wavelength, emission
wavelength and quantum yield or brightness. The excita-
tion wavelength is the optimal wavelength of external light
to bring the ﬂuorophore to its exited state. The emission
wavelength is the wavelength of the photons emitted upon
relaxation. Usually, the emitted photons have a longer
wavelength than the photons used for excitation and thus,
the emitted photons have a lower energetic value. The
brightness or quantum yield of a ﬂuorophore is deﬁned by
the fraction of molecules that emit a photon after direct
excitation by the excitation light source. In most cases this
value is nearly the same value as the ratio between the
number of photons emitted from a bulk sample and the
total number of absorbed photons [8]. All three of these
properties, excitation wavelength, emission wavelength
and quantum yield, have important implications for the use
of a certain ﬂuorophore for imaging [9].
When using ﬂuorescence for in vivo imaging, tissue
absorbance, scattering and auto-ﬂuorescence can become a
problem especially when imaging structures deeper in the
animal. Most auto-ﬂuorescence occurs in the green part of
the spectrum [9, 10]. The amount of auto-ﬂuorescence
rapidly decreases when shifting towards a longer excitation
wavelength, the red parts of the spectrum. Near infrared
(IR) light causes hardly any auto-ﬂuorescence [10–12].
Moreover, light penetration, tissue absorption and scatter-
ing are greatly reduced at the near infrared end of the
spectrum compared to green light.
Recently ﬂuorescent proteins with increasingly longer
emission maxima (up to 649 nm), like the series of red
shifted proteins obtained by mutating dsRed, i.e., mFruits
like mCherry, mTomato and mPlum [13, 14], and a series
of recently developed very bright, red-shifted proteins
derived from the anemone Entacmaea quadricolor like
Katushka and mKate [12], have been developed. The
longer emission wavelengths lead to a reduction of back-
ground auto-ﬂuorescence and substantially increase tissue
penetration. Moreover, the newest generation of mamma-
lian expressed ﬂuorescent proteins, based on bacterial
phytochromes, enter the near infrared with emission
spectra exceeding wavelengths of 700 nm [15].
Both luciferase for BLI and various ﬂuorescent proteins
for FLI can be expressed in cells or animals. Using speciﬁc
promoters to drive reporter gene expression, these imaging
modalities can be used not only for localization but can
also provide functional information.
Whole body optical imaging instruments
In the last decade there has been a rapid growth of optical
imaging applications in small animal models driven by
creative approaches to apply these techniques in biomedi-
cal research and also by the availability of innovative
instruments. Most of the BLI imaging systems provide 2-
dimensional planar information in small animals, showing
the locations and intensity of light emitted from the animal
in pseudo-color scaling. Nowadays, there are many com-
mercial whole-body pre-clinical BLI systems on the
market.
However, in its planar projection form, BLI is non-
quantitative and its spatial resolution is relatively poor.
Interestingly, recent developments in bioluminescence
tomography promise to provide three dimensional quanti-
tative source information with improved spatial resolution
[16–18].
BLI imaging systems that are able to image moving
objects have been developed for experiments in which
anesthesia is a problem. Examples of such real time
imaging systems are the IVIS Kinetic (Caliper Life
Sciences Inc.) and the Photon Imager (Biospace Lab)
[19, 20].
In analogy with BLI technology, the vast majority of
applications of in vivo small animal ﬂuorescence imaging
are based on planar epi-illumination imaging. However, an
important part of the research conducted in whole-body
small animal imaging is concerned with the development
of novel ﬂuorescence tomography approaches pushing
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quantiﬁcation and spatial resolution [21].
New FLI systems are able to capture spectral informa-
tion of each pixel of an image. The spectral information
can be unmixed to reveal all the different spectra that,
taken together, form the actual image. By doing so, it is
possible to identify multiple ﬂuorescent labels within an
image and to remove background (auto-)ﬂuorescence. This
way of analyzing spectral data within ﬂuorescence datasets
is called spectral unmixing [22, 23].
Gene reporter systems
Whole body imaging of VEGF signaling
VEGF is one of the key factors regulating angiogenesis.
Most of the vasculogenic and angiogenic effects of VEGF
are mediated through the VEGF receptor 1 (VEGFR1,
FLT-1) and VEGF receptor 2 (VEGFR2, Flk-1) expressed
on endothelial cells [24]. During angiogenesis, including
tumor angiogenesis, both VEGF and VEGFR2 expression
are locally upregulated [25–28]. VEGF receptors and
VEGF itself are attractive targets for molecular imaging
given their important role and upregulated expression
during (tumor) angiogenesis. As a result, several models
have been developed to image and quantify VEGF receptor
and VEGF expression.
To monitor VEGFR2 gene expression in vivo as a read-
out for angiogenesis, in real time, Zhang et al. [29]
developed a VEGFR2-luciferase transgenic mouse model
(FVB/N-Tg(VEGFR2-luc)-Xen). In this mouse, luciferase
expression is under control of the VEGFR2 promoter
region [30] causing endothelial cells lining the angiogenic
blood vessels to express luciferase. The VEGFR2-luc
mouse has been validated using cutaneous wound healing
models in which VEGFR2 expression was upregulated at
the site of a punch wound marked by a clear localized
increase of the luciferase signal. The increase in VEGFR2
gene activation reached a maximum after 7–10 days after
the wound was inﬂicted [29]. These ﬁndings were consis-
tent with later studies which used the same mouse model
[31, 32].
Co-registration of BLI and FLI makes it possible to
follow multiple processes in one mouse, for instance tumor
growth and angiogenesis. As an example, we used the
murine breast cancer cell line SMF [33] and the VEGFR2-
luc knock-in mouse [29]. A VEGFR2-luc knock-in mouse
received an orthotopic inoculation with red ﬂuorescent
SMF-mCherry breast cancer cells (right side of the animal)
and wild type SMF cells (left side of the animal. The
ﬂuorescent signal from the SMF-mCherry cells and bio-
luminescent signal from the locally upregulated VEGFR2
expression enabled the simultaneous imaging and quanti-
ﬁcation of angiogenesis and tumor growth real time in
vivo. We show the increase in tumor size from week 2 to
week 4 using FLI. The FLI signal is only detected at the
site of the ﬂuorescent tumor, not at the site with the wild
type tumor. The pro-angiogenic response is visualized with
BLI both at the site of the ﬂuorescent tumor as well as the
site with the wild type tumor (Fig. 1). This way, both tumor
growth and pro-angiogenic signaling can be quantiﬁed
simultaneously, the ratio of which can be used as a measure
for angiogenic characteristics of certain tumors.
Other in vivo approaches to study VEGF signaling and
angiogenesis in real time are transgenic mouse models
which express green ﬂuorescent protein (GFP) or luciferase
driven by the VEGF promoter, namely the ﬂuorescent
VEGF/GFP [34] and the bioluminescent pVEGF-TSTA-ﬂ
transgenic models [35]. The latter approach makes use of
the GAL4-VP16 two step transcriptional ampliﬁcation
(TSTA) system [36] to amplify luciferase expression. In
this system, the full length human VEGF promoter is
placed upstream of the gene encoding a GAL4-VP16
fusion protein. This fusion protein binds GAL4 binding
sites that are placed upstream of an adenovirus E4 TATA
minimal promoter. This promoter drives luciferase gene
expression resulting in GAL4-induced luciferase expres-
sion [35]. The extra step via GAL4-VP16 leads to an
ampliﬁcation in luciferase expression. The TSTA system
has been used previously shown to amplify prostate spe-
ciﬁc luciferase expression leading to a 50-fold increase
compared to the direct, one step system [36].
Wang et al. [35] demonstrated the correlation between
VEGF expression and BLI signal both in vitro and in vivo.
In addition, they showed that this transgenic animal can be
used to study the VEGF response in both wound healing
assays as well as tumor growth models (Fig. 2).
In vivo imaging of vasculature
The VEGF and VEGFR2 reporter mice make it possible to
image the areas in which there is an increased pro-angio-
genic and vasculogenic signaling. Other transgenic animal
models have been developed to image the actual existing
vasculature. These models include several transgenic ani-
mals with endothelial speciﬁc expression of ﬂuorescent
proteins like GFP, e.g., the Tie2-GFP mice [37, 38] and the
eNOS-GFP mouse [39]. The GFP models are well suited
for in vivo microscopic and confocal approaches in con-
trast to the whole body optical imaging models discussed
above.
The Tie2-GFP nude mouse expresses GFP under
direction of the endothelial speciﬁc receptor tyrosine
kinase (Tie2). This mouse is well suited to study angio-
genesis and interactions between various (human) tumor
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123xenografts and tumor vasculature in vivo due to its athymic
nude background. The non-invasive character of ﬂuores-
cence imaging allows follow up over time and assessment
of anti-angiogenic treatment efﬁcacy in vivo (Fig. 3)[ 37].
The eNOS-GFP. mouse expresses GFP driven under the
endothelial speciﬁc promoter of endothelial nitric oxide
synthase (eNOS) [39]. A dorsal skinfold chamber can be
used to visualize the interaction between tumor cells and
growing vasculature. In such a setup, the skin on the back
of a mouse is stretched and ﬁtted between two glass slides
allowing in vivo microscopy. When SMF-mCherry cells
are inoculated between these glass slides, confocal
microscopy allows the ﬂuorescent imaging of both tumor
growth (mCherry) and developing tumor vasculature (GFP)
in such a dorsal skin-fold chamber (Fig. 4).
Yang et al. [40] used wild type mice and GFP positive
tumor xenografts to follow tumor angiogenesis in real time.
The blood vessels appear as dark contrast against the bright
ﬂuorescent tumor. This way they were able to image,
quantify and follow the vessel density in orthotopically
transplanted tumors over time either by whole body
imaging or intravital examination. In a similar approach,
dual-color imaging of red ﬂuorescent tumor xenografts in a
mouse expressing GFP driven by the chicken b-actin pro-
moter and cytomegalovirus enhancer [41] was demon-
strated [42]. In this model the tumor vasculature and other
host-derived stromal cell types such as ﬁbroblasts appear in
green within the red ﬂuorescent tumor [41].
Another transgenic mouse model to study angiogenesis
and nascent vasculature is the GFP mouse in which GFP
expression is driven by the regulatory elements of the
nestin gene. Nestin is a marker for neural stem cells, neural
progenitor cells and neuro-epithelial stem cells [43]. This
so-called nestin regulatory element–driven-GFP (ND-GFP)
mouse was originally developed in order to study the self
renewal capabilities of neural stem cells and progenitor
cells [43–45]. In addition to neural cell types, nestin is
expressed in the hair follicular bulge as well [46]. During
the murine hair cycle, pronounced vascular remodeling
occurs with more than a fourfold increase in perifollicular
vessel size [47]. It has been found in the ND-GFP mouse
that besides the follicular bulge, the perifollicular nascent
blood vessels were GFP and thus nestin positive [48, 49].
By transplanting follicles from the ND-GFP mice into nude
mice it became clear that follicle derived cells gave rise to
these newly formed perifollicular blood vessels. The peri-
follicular blood vessels connected with the existing vas-
culature of the receiving animal. Moreover, the newly
formed GFP positive vessels expressed the endothelial cell
speciﬁc marker CD31 conﬁrming that these vessels were
indeed blood vessels [48]. In addition, it has been shown
that follicle derived vessel growth was increased near
wounded skin and that the GFP positive vessels grew from
the transplanted follicle towards the wound [48]. Later
studies have conﬁrmed the ND-GFP mouse can be used as
a model to image nascent tumor vasculature in the skin,
mammary fat pad, pancreas, liver, lung, bone and colon
[50–55].
One of the most recent mouse models, the Tie-2-Biotag
mouse, makes use of the highly speciﬁc and strong binding
Fig. 1 Multi-modality imaging of tumor growth and angiogenesis. A
VEGFR2-luc knock-in mouse was orthotopically, i.e., in the mam-
mary fat pad, inoculated with 1 9 10
6 SMF-mCherry cells (marked
with asterisk) and SMF wild-type cells (marked with ﬁlled diamond),
a murine breast cancer cell line. SMF-mCherry cells constitutively
express the far red ﬂuorescent protein mCherry, which accumulates in
the cytoplasm. Mice were imaged at week 2 and week 4 both FLI (a)
and BLI (b) using the IVIS Spectrum (Caliper LifeSciences, USA)
camera system. a Tumor growth of the mCherry positive tumor could
be followed over time using FLI. b The BLI signal was present at the
site of both the mCherry positive and negative tumors indicating a
local upregulation of VEGFR2 expression and tumor angiogenesis.
(Snoeks et al. unpubl. results)
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123Fig. 2 Induction of ﬂ
expression during wound
healing in a pVEGF-TSTA-ﬂ
transgenic mouse. a mouse was
imaged before wound creation
in the CCD camera (day 0) and
imaged again subsequent to
wound creation every 4–5 days
using D-luciferin (150 mg/kg
ip). b Optical CCD images of
four pVEGF-TSTA-ﬂ transgenic
mice (mice 1–4) on days 19, 20,
21, and 22 after creation of the
wound. Arrows indicate the
position of the wounds.
c Correlation plot of maximum
bioluminescence signal
(ps
-1cm
-2sr
-1) vs.
endogenous VEGF levels in the
wound tissue (r
2 = 0.70). Error
bars represent the standard error
for triplicate samples in the
ELISA assay. (d) pVEGF-
TSTA-ﬂ transgenic mice were
injected subcutaneously with
5 9 106 NK2 (FVB/N mouse
mammary tumor cell line) cells
in the lower right ﬂank. Mice
were imaged on day 4 and
subsequently every few days
until day 29 using D-luciferin as
the reporter substrate (150 mg/
kg, injected ip). CCD camera
imaging revealed a detectable
bioluminescence signal in the
area around the tumor on day 4.
Signal intensity continued to
increase until day 17, after
which a considerable decline in
signal was observed
(days 22–29). (Adapted with
permission from Wang et al.
Physiol Genomics. 2006 Jan 12;
24(2):173–80. [35])
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123of avidin to biotin, commonly used in immunohistochem-
ical staining techniques. In order to do so, this mouse
expresses Biotin Ligase (BirA) and a cluster of BirA sub-
strate sequences (Biotags) fused to a transmembrane
domain under control of the endothelial cell speciﬁc Tie2
promoter. Cells expressing this Biotag-BirA cassette can be
targeted in vivo with avidinated probes of choice. These
transgenic mice, in which vascular endothelial cells are
biotinylated already during angiogenesis, are highly useful
for targeted in vivo imaging of angiogenesis and estab-
lished vasculature using avidinated agents suitable for any
desired imaging modality [56].
Fig. 3 GFP vessels in the athymic Tie2-GFP transgenic adult mouse.
a–g Images from heart, kidney, liver, spleen, lung, brain, and calf
muscle, respectively. Scale bar represents 20 lm. h–j Intr. avital
ﬂuorescence microscopy images of GFP vessels in the muscle (h–i)
and in the ear skin (j). (Reprinted from Hillen F, Kaijzel EL,
Castermans K, oude Egbrink MG, Lowik CW, Grifﬁoen AW. A
transgenic Tie2-GFP athymic mouse model; a tool for vascular
biology in xenograft tumors. Biochem Biophys Res Commun 2008;
368:364–7. [37])
Fig. 4 In vivo ﬂuorescent microscopy of tumor vasculature. An
eNOS-GFP mouse received a subcutaneous inoculation with 1 9 10
6
SMF-mCherry cells in a dorsal skinfold chamber. Images were taken
using a Zeiss CLSM 510 Meta microscope with a 109 objective. The
following excitation lasers and emission ﬁlters were used, green: laser
488 nm, ﬁlter BP 505–550 nm, red: laser 543 nm, ﬁlter BP 560–
615 nm. a Green ﬂuorescent vasculature. b Red ﬂuorescent tumor-
cells. c Superimposed images of the vasculature and tumorcells
(Kaijzel, Ten Hagen et al. unpubl. results)
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123Optical imaging of hypoxia
Hypoxia and the subsequent stabilization of hypoxia
inducible factor-1 (HIF-1) is one of the key initiators of
(tumor-)angiogenesis as reviewed by Liao and Jonson [57].
Inshort,HIF-1hasanoxygendependentdegradationdomain
(ODD) which is hydroxylated in an oxygen dependent
manner by prolyl hydroxylases. As a result, the ODD binds
the Von Hippel-Lindau factor (VHL) under normoxic con-
ditions, targeting HIF-1 for proteasomal degradation. VHL
cannot bind HIF-1 under hypoxic conditions, leading to
stabilization of HIF-1 and downstream signaling [58].
The promoter regions of most genes upregulated under
hypoxic conditions, amongst which VEGF, contain a
hypoxia responsive element (HRE). This HRE is the HIF-1
target binding site [59]. To enable real time measurement of
bothinvivoaswellasinvitroHIF-1activityseveralreporter
constructs have been developed in which reporter gene
expression such as luciferase [60–62] or GFP [63, 64], is
drivenbyHREs.ThepresenceofHIF-1leadstoasigniﬁcant
upregulation of the reporter gene expression. HRE-Lucif-
erase reporter constructs have been shown to be valuable
tools to evaluate tumor hypoxia and the efﬁcacy of hypoxia
directed therapies in vivo (Fig. 5)[ 61, 62]. Biolumines-
cence, a process requiring ATP and O2, did not seem to be
hampered by the low oxygen tension in the tissue.
In another approach to visualize hypoxic signaling and
HIF-1 stabilization, reporter cell lines, constitutively
expressingafusionproteinconsistingoftheODDcoupledto
luciferase, have been generated [65]. Slightly different
models are reporter cell lines in which express a HIF-
1:luciferase fusion protein [61, 66]. In both reporter cell
lines, luciferase will be degraded immediately under
normoxicconditions,sonoluciferasesignalcanbedetected.
Under hypoxic conditions, luciferase will be stabilized in a
similar manner as HIF-1 which will result in a detectable
signal. These imaging tools are useful for studying the
biology of tumor hypoxia and mechanisms of response to
experimental antiangiogenic therapy.
Fluorescent probes
In addition to the bioluminescent and ﬂuorescent gene
reporter systems discussed above, various ﬂuorescent pro-
tease-sensing probes and targeted probes have been
developed. The ﬁrst protease-sensing optical probes were
autoquench ﬂuorescent probes that convert from a
nonﬂuorescent to a ﬂuorescent state by proteolytic activa-
tion of lysosomal cysteine or serine proteases like cathep-
sin-B [67]. The utility of these probes has also been
extended to other enzymes such as thrombin and matrix
metalloproteinase-2 by inserting enzyme-speciﬁc peptide
stalks between the carrier and the ﬂuorochromes [67–70].
Targeted probes consist of a ﬂuorophore coupled to a
highly speciﬁc antibody or single chain lama-antibodies,
afﬁbodies or ligands.
avb3 targeted probes
The avb3 integrin plays a crucial role during tumor angio-
genesis. It is highly expressed on endothelial cells of newly
formed tumor vasculature and on various tumor cells,
whereasquiescentendothelialcellsandothernon-cancerous
cellsarelargelyavb3negative.TheaminoacidsequenceArg-
Gly-Asp (RGD), also present in matrix molecules like
Fig. 5 In vivo monitoring of the stabilization of HIF-1a using
bioluminescence imaging. a pcDNA3.1-mHIF-1a-luciferase (HIF-1a-
luc) and pcDNA3.1-luciferase (luciferase) reporter constructs.
b Immunoﬂuorescence staining of ﬁreﬂy luciferase in MEF cells
transiently transfected with pcDNA3.1-mHIF-1a-luciferase. Nuclei
were stained with DAPI. (Magniﬁcation: 9 300.) c Assessment of
oxygen-dependent regulation and transcriptional activity of the HIF-
1a-luciferase fusion construct. MEF-Hif1a ?/? or MEF-Hif1a -/-
were cotransfected with pcDNA3.1 mHIF-1a-luciferase, and the
reporter plasmid pH3SVB, which drives the expression of
b-galactosidase from a HIF responsive promoter. b-Galactosidase
activity was assessed. Data are representative of 2 independent
experiments. d Bioluminescent images of a mouse carrying a HIF-1a-
luciferase C51 tumor in the neck. Four consecutive images of the
same animal are shown. Color bar indicates total photon counts.
e Normalized bioluminescence photon counts (mean ± SEM) relative
to day 5 values for both the HIF1a-luciferase and the luciferase
control tumors. Values indicated by asterisk signiﬁcantly (P B 0.05)
differ from values measured in control groups. (Adapted with
permission from Lehmann et al. Proc Natl Acad Sci USA. 2009
Aug 18; 106(33):14004–9. Epub 2009 Jul 31. [61])
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123vibronectin, is a tripeptide that selectively binds to integrin
receptors including avb3 and avb5 [71–73]. The activation of
avb3 integrin is not limited to tumor biology and thus probes
targeting avb3 integrin can be a valuable tool to study other
processes and diseases as well, for example angiogenesis,
atherosclerosis, inﬂammation, bone remodeling and arthritis.
Based on the binding of RGD to avb3 integrin, Haubner
et al. [74] developed
125I and later
18F[ 75] labeled tracers
to image avb3 integrin expression and tumor angiogenesis.
In recent years, many ﬂuorescently labeled cyclic RGD
peptides have been developed for near infrared ﬂuores-
cence imaging like RGD-Cy7, RGD-Cy5.5, RGD-QD705
[76–78] and cyclic RGD coupled to IRDye 800CW-labeled
peptide which is even more shifted towards the infrared
parts of the spectrum resulting in ideal ﬂuorescent
characteristics for in vivo use [79, 80]. Mulder et al. [81,
82] recently described paramagnetic lipid-encapsulated
quantum dots with RGD presented at the outside and a
green ﬂuorescent quantum dot at the inside of the micellar
shell. These targeted particles are both suitable for ﬂuo-
rescence imaging as well as magnetic resonance imaging
(MRI), thus providing unique opportunities for the use of
multi modality molecular imaging.
Several groups have improved avb3 integrin speciﬁcity,
binding afﬁnity, and possible targeted delivery of therapeu-
tics, by coupling multiple RGD motifs on a backbone mol-
ecule [81–85]. Although many types of tumor cells are
positive for avb3 integrin, RGD-modiﬁed proteins mainly
localize at the tumor endothelium and not in the tumor itself
[86].
Fig. 6 Effect of antiangiogenic Avastin treatment on avb3 integrin
and cathepsin B signals in A673 tumor-bearing mice. a Representa-
tive volume renderings of IntegriSense and ProSense. Note the
differential localization of ﬂuorescent signal with IntegriSense and
ProSense in the same animals (IntegriSense in blue and ProSense in
red). b Quantiﬁcation of tumor ﬂuorescence shows that IntegriSense
and Prosense signal in tumors is decreased following Avastin
treatment (P = 0.0008 and P = 0.013, respectively). c Avastin also
signiﬁcantly inhibits tumor growth as determined by tumor volume
calipers measurements (by 58.4%, P = 0.022). (Reprinted from
Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho
G, Blusztajn A, Cuneo G, Zhang J, Jensen J, Hargreaves R, Coleman
P, Hartman G, Rajopadhye M, Duong LT, Sur C, Yared W, Peterson
J, Bednar B. Dual In Vivo Quantiﬁcation of Integrin-targeted and
Protease-activated Agents in Cancer Using Fluorescence Molecular
Tomography (FMT). Mol Imaging Biol 2009. [87])
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(NIRF) probe IntegriSense (Visen Medical) consists of a
small molecule nonpeptide avb3 antagonist fused to the
VivoTag-S680 near infrared ﬂuorophore. IntegriSense has a
much higher speciﬁcity for avb3 integrin compared to RGD-
based probes. Unlike RGD-based probes, extravasation of
IntegriSense does occur and the probe localizes at both at
the surface of avb3integrin positive endothelial cells and the
surface of avb3 integrin positive tumor cells. Furthermore,
IntegriSense is internalized by avb3 integrin positive tumor
cells leading to a slower clearance of the probe from tumors
compared to the surrounding tissues. A drawback of the
slower clearance from a tumor is the practical upper limit on
the possible frequency of repeated measurements [87].
Using ﬂuorescence-mediated tomography (FMT), Koss-
odo et al. [87] measured tumor volume and vascularization
in A673 tumor-bearing mice. They used IntegriSense to
visualize blood vessels and ProSense, a cathepsin-based
protease activated ﬂuorescent probe which only ﬂuoresces
after being cleaved by proteases, to visualize the tumor. In
addition they were able to quantify the effect of antiangio-
genic treatment (Fig. 6).
VEGF-receptor targeted probes
The VEGFR-2 is a very attractive endothelial target for
imaging of tumor angiogenesis due to its temporal and
local upregulation during (tumor-)angiogenesis [24–28].
To target the VEGFR-2, Backer et al. [88] used single
chain VEGF (scVEGF) with an N-terminal cysteine-con-
taining tag (Cys-tag) which can be used for site speciﬁc
attachment of various agents [89]. The scVEGF-based
family of probes has been validated to target the VEGF
receptor in vitro and in vivo tumor angiogenesis [90, 91].
More recently, scVEGF labeled with the near infrared dye
Cy5.5 has been used for ﬂuorescence imaging of VEGF
receptor in angiogenic vasculature, in regions of sterile
inﬂammation and during tumor angiogenesis [92, 93].
Long circulating ﬂuorescent agents
Long circulating blood pool macromolecules labeled with
gadoliniumhavebeenusedastraditionalMRIcontrastagent
for determining vascular volumes [94]. The rapid advance-
ments in ﬂuorescence imaging lead to the need for long
circulating ﬂuorescent agents. The ﬁrst generation of these
ﬂuorescentprobeswasbased onlongcirculating dextrinated
iron oxide (LCDIO) preparations coupled to a ﬂuorescent
label [95–97]. These probes were used by Bremer et al. [97]
to determine the tumoral vascular volume fractions by MRI
validated with ﬂuorescence intravital microscopy.
With the development of FMT for small laboratory ani-
mals the imaging focus shifted from intravital microscopy to
3D whole body imaging. Using the commercially available
near IR ﬂuorochrome labeled long circulating synthetic graft
copolymer AngioSense-750 and the ﬂuorescently labeled
Fig. 7 Dual target imaging. Mice bearing xenograft tumors (either
breast cancers or gliosarcomas) were imaged at two different
wavelengths to map angiogenesis (a 748 nm) and HER-2/neu (b
672 nm) in the same animal. The gliosarcoma is largely devoid of
HER-2/neu. c a combined three-dimensional map of both processes.
(Adapted with permission from Montet et al. Cancer Res. 2005 Jul 15;
65(14):6330–6. Fig. 4 [95])
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demonstrated the possibility to co-register angiogenesis and
tumor growth with FMT. In their experiment they used a
Her2/neupositivebreastcancerxenograftmodelandaglioma
model with low expression of Her2/Neu (Fig. 7). In later
studies they conﬁrmed that FMT allows quantitative visual-
ization of tumoral vascular volume fractions in mice using
Herceptin-Cy5.5,AngioSense-680andAngioSense-750[98].
Both AngioSense-680 and AngioSense-750 are ﬂuorescently
labeledlongcirculatingsyntheticgraftcopolymersoptimized
for 680 and 750 nm excitation wavelengths, respectively.
Conclusion and future directions
Here we discussed a great number of optical imaging
models that can be used to image the angiogenic process on
various levels ranging from intravital microscopy to whole
body imaging. The cost effective and non invasive char-
acter of optical imaging makes it an ideal imaging modality
for repeated measurements and to follow treatment
response of anti-angiogenic treatment over time. New
imaging systems, that are able to unmix signals of various
wavelengths, make it possible to study various ﬂuorescent
and luminescent signals simultaneously. This offers a
powerful tool to study different processes and interactions,
for example tumor growth and angiogenesis, in the same
animal. Furthermore, optical imaging can be combined
with various other imaging modalities, for example the
ﬂuorescent paramagnetic avb3 targeted probes with MRI
contrast that offer the opportunity to image angiogenesis at
high resolution with MRI while conﬁrming the speciﬁcity
of the MRI contrast with the co-localized ﬂuorescent sig-
nal. The development of less toxic near infrared ﬂuorescent
probes open up the opportunity to apply ﬂuorescence
imaging in various clinical settings in the near future.
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